341 related articles for article (PubMed ID: 18246013)
1. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis.
Joseph V; Rampersaud YR
Spine (Phila Pa 1976); 2007 Dec; 32(25):2885-90. PubMed ID: 18246013
[TBL] [Abstract][Full Text] [Related]
2. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
3. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
4. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
5. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine.
Chrastil J; Low JB; Whang PG; Patel AA
Spine (Phila Pa 1976); 2013 Jul; 38(16):E1020-7. PubMed ID: 23629484
[TBL] [Abstract][Full Text] [Related]
6. Cantilever TLIF with structural allograft and RhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome.
Anand N; Hamilton JF; Perri B; Miraliakbar H; Goldstein T
Spine (Phila Pa 1976); 2006 Sep; 31(20):E748-53. PubMed ID: 16985443
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
8. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
9. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
Roh JS; Yeung CA; Field JS; McClellan RT
J Orthop Surg Res; 2013 Dec; 8():49. PubMed ID: 24373225
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review.
Mindea SA; Shih P; Song JK
Spine (Phila Pa 1976); 2009 Jun; 34(14):1480-4; discussion 1485. PubMed ID: 19525840
[TBL] [Abstract][Full Text] [Related]
12. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.
Mummaneni PV; Pan J; Haid RW; Rodts GE
J Neurosurg Spine; 2004 Jul; 1(1):19-23. PubMed ID: 15291015
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
[TBL] [Abstract][Full Text] [Related]
14. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.
Villavicencio AT; Burneikiene S; Nelson EL; Bulsara KR; Favors M; Thramann J
J Neurosurg Spine; 2005 Dec; 3(6):436-43. PubMed ID: 16381205
[TBL] [Abstract][Full Text] [Related]
15. Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.
Christensen TJ; Annis P; Hohl JB; Patel AA
Spine J; 2014 Jun; 14(6):e23-8. PubMed ID: 24291359
[TBL] [Abstract][Full Text] [Related]
16. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2).
McClellan JW; Mulconrey DS; Forbes RJ; Fullmer N
J Spinal Disord Tech; 2006 Oct; 19(7):483-6. PubMed ID: 17021411
[TBL] [Abstract][Full Text] [Related]
17. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
[TBL] [Abstract][Full Text] [Related]
18. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases.
Lewandrowski KU; Nanson C; Calderon R
Spine J; 2007; 7(5):609-14. PubMed ID: 17526434
[TBL] [Abstract][Full Text] [Related]
19. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
Slosar PJ; Josey R; Reynolds J
Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
[TBL] [Abstract][Full Text] [Related]
20. Exploratory meta-analysis on dose-related efficacy and morbidity of bone morphogenetic protein in spinal arthrodesis surgery.
Hofstetter CP; Hofer AS; Levi AD
J Neurosurg Spine; 2016 Mar; 24(3):457-75. PubMed ID: 26613283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
